Jane Street
BCRX icon

Jane Street’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jane Street’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529K Sell
55,595
-302,405
-84% -$2.35M ﹤0.01% 7919
2025
Q4 		$2.79M Buy
358,000
+43,500
+14% +$314K ﹤0.01% 4167
2025
Q3 		$2.39M Buy
314,500
+38,100
+14% +$317K ﹤0.01% 4616
2025
Q2 		$2.48M Sell
276,400
-3,900
-1% -$36.3K ﹤0.01% 4084
2025
Q1 		$2.1M Sell
280,300
-126,000
-31% -$1.02M ﹤0.01% 4271
2024
Q4 		$3.06M Sell
406,300
-55,900
-12% -$424K ﹤0.01% 3411
2024
Q3 		$3.51M Sell
462,200
-449,800
-49% -$3.42M ﹤0.01% 3449
2024
Q2 		$5.64M Sell
912,000
-4,200
-0.5% -$23.2K ﹤0.01% 2799
2024
Q1 		$4.65M Buy
916,200
+26,000
+3% +$146K ﹤0.01% 2717
2023
Q4 		$5.33M Buy
890,200
+577,200
+184% +$3.34M ﹤0.01% 2762
2023
Q3 		$2.22M Buy
313,000
+122,700
+64% +$882K ﹤0.01% 3878
2023
Q2 		$1.34M Sell
190,300
-190,100
-50% -$1.53M ﹤0.01% 4758
2023
Q1 		$3.17M Sell
380,400
-31,900
-8% -$307K ﹤0.01% 3058
2022
Q4 		$4.73M Buy
412,300
+122,600
+42% +$1.53M ﹤0.01% 2564
2022
Q3 		$3.65M Sell
289,700
-44,400
-13% -$571K ﹤0.01% 3135
2022
Q2 		$3.54M Buy
334,100
+111,200
+50% +$1.15M ﹤0.01% 3185
2022
Q1 		$3.62M Sell
222,900
-47,800
-18% -$767K ﹤0.01% 3597
2021
Q4 		$3.75M Sell
270,700
-130,900
-33% -$1.73M ﹤0.01% 3307
2021
Q3 		$5.77M Sell
401,600
-44,100
-10% -$695K ﹤0.01% 2512
2021
Q2 		$7.05M Buy
445,700
+125,100
+39% +$1.7M ﹤0.01% 2153
2021
Q1 		$3.26M Buy
320,600
+230,200
+255% +$2.37M ﹤0.01% 3091
2020
Q4 		$673K Buy
90,400
+25,200
+39% +$130K ﹤0.01% 5293
2020
Q3 		$224K Buy
+65,200
New +$279K ﹤0.01% 6287

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Jane Street's BCRX Position: Q1 2026 in Review

Jane Street reduced its BioCryst Pharmaceuticals (BCRX) stake by 4.1% in Q1 2026, selling an estimated $208K and leaving 622,607 shares worth $5.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Jane Street first reported a position in BCRX in Q2 2013 and has held it in 36 quarters since. The position peaked at $14M in Q3 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Jane Street held 622,607 shares of BioCryst Pharmaceuticals worth $5.93M as of Q1 2026.
  • Jane Street sold 26,750 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $208K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3259 holding.
  • Jane Street first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Jane Street's BioCryst Pharmaceuticals position peaked at $14M in Q3 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.